| $385M | ||
| $350M | ||
| $107M | ||
| $100M | ||
| $91M | ||
| $83M |
Buys | $215,297,266 | 3 | 6 |
Sells | $86,289,096 | 46 | 94 |
| BAKER BROS. ADVISORS LP | director | 2 | $201.34M | 0 | $0 | $201.34M |
| BVF PARTNERS L P/IL | See Remarks and Footnotes | 1 | $13.96M | 0 | $0 | $13.96M |
| Albers Jeffrey W. | director | 0 | $0 | 2 | $744,772 | $-744,772 |
| Goodman Noah | Chief Business Officer | 0 | $0 | 3 | $1.02M | $-1.02M |
| Ridloff Elena | director | 0 | $0 | 4 | $1.51M | $-1.51M |
| Esposito Pamela | director | 0 | $0 | 4 | $3.05M | $-3.05M |
| Jacobs Bruce N. | Chief Financial Officer | 0 | $0 | 3 | $5.05M | $-5.05M |
| Gollob Jared | Chief Medical Officer | 0 | $0 | 5 | $9.13M | $-9.13M |
| Chadwick Jeremy G | Chief Operating Officer | 0 | $0 | 12 | $15.6M | $-15.6M |
| Mainolfi Nello | Chief Executive Officer | 0 | $0 | 6 | $19.7M | $-19.7M |
| Booth Bruce | director | 0 | $0 | 7 | $30.47M | $-30.47M |
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Over the last 12 months, insiders at Kymera Therapeutics, Inc. have bought $215.3M and sold $86.29M worth of Kymera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kymera Therapeutics, Inc. have bought $58.12M and sold $60.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $201.34M. BVF PARTNERS L P/IL (See Remarks and Footnotes) — $13.96M.
The last purchase of 2,005,813 shares for transaction amount of $172.5M was made by BAKER BROS. ADVISORS LP () on 2025‑12‑11.
| 2026-05-27 | Sale | Chadwick Jeremy G | Chief Operating Officer | 4,279 0.0052% | $81.58 | $349,096 | -8.02% | |
| 2026-05-26 | Sale | Chadwick Jeremy G | Chief Operating Officer | 12,905 0.0152% | $79.36 | $1.02M | -5.77% | |
| 2026-05-11 | Sale | Ridloff Elena | director | 3,000 0.0038% | $87.00 | $261,000 | -5.27% | |
| 2026-04-29 | Sale | Mainolfi Nello | Chief Executive Officer | 30,000 0.0356% | $81.18 | $2.44M | -1.06% | |
| 2026-04-22 | Sale | Chadwick Jeremy G | Chief Operating Officer | 300 0.0004% | $90.00 | $27,000 | -8.60% | |
| 2026-04-22 | Sale | Booth Bruce | director | 6,000 0.0074% | $89.96 | $539,772 | -8.60% | |
| 2026-04-15 | Sale | Chadwick Jeremy G | Chief Operating Officer | 1,300 0.0016% | $90.00 | $117,000 | -8.30% | |
| 2026-04-15 | Sale | Booth Bruce | director | 5,335 0.0066% | $90.04 | $480,354 | -8.30% | |
| 2026-04-14 | Sale | Chadwick Jeremy G | Chief Operating Officer | 5,251 0.0066% | $90.00 | $472,598 | -8.86% | |
| 2026-04-14 | Sale | Goodman Noah | Chief Business Officer | 1,347 0.0017% | $90.00 | $121,230 | -8.86% | |
| 2026-04-14 | Sale | Booth Bruce | director | 4,159 0.0052% | $89.97 | $374,185 | -8.86% | |
| 2026-04-10 | Sale | Goodman Noah | Chief Business Officer | 2,000 0.0024% | $87.35 | $174,700 | -3.05% | |
| 2026-04-09 | Sale | Goodman Noah | Chief Business Officer | 8,264 0.0104% | $87.50 | $723,082 | -5.31% | |
| 2026-04-01 | Sale | Chadwick Jeremy G | Chief Operating Officer | 14,640 0.018% | $85.46 | $1.25M | -1.42% | |
| 2026-04-01 | Sale | Ridloff Elena | director | 4,600 0.0057% | $85.42 | $392,922 | -1.42% | |
| 2026-03-31 | Sale | Chadwick Jeremy G | Chief Operating Officer | 7,600 0.0095% | $85.38 | $648,882 | +0.67% | |
| 2026-03-31 | Sale | Ridloff Elena | director | 7,400 0.0093% | $85.37 | $631,739 | +0.67% | |
| 2026-03-25 | Sale | Chadwick Jeremy G | Chief Operating Officer | 24,727 0.0308% | $80.26 | $1.98M | +5.85% | |
| 2026-03-23 | Sale | Chadwick Jeremy G | Chief Operating Officer | 91,250 0.1124% | $77.41 | $7.06M | +8.23% | |
| 2026-03-20 | Sale | Esposito Pamela | director | 2,500 0.0031% | $79.15 | $197,877 | +6.53% |
| BAKER BROS. ADVISORS LP | 7955916 9.672% | $611.89M | 3 | 0 | <0.0001% | |
| BVF PARTNERS L P/IL | See Remarks and Footnotes | 2798795 3.4025% | $215.26M | 9 | 0 | +27.91% |
| Mainolfi Nello | Chief Executive Officer | 666195 0.8099% | $51.24M | 0 | 33 | |
| Jacobs Bruce N. | Chief Financial Officer | 232588 0.2828% | $17.89M | 0 | 14 | |
| Gollob Jared | Chief Medical Officer | 117134 0.1424% | $9.01M | 0 | 22 | |
| Goodman Noah | Chief Business Officer | 50195 0.061% | $3.86M | 0 | 3 | |
| Chadwick Jeremy G | Chief Operating Officer | 44018 0.0535% | $3.39M | 0 | 15 | |
| Booth Bruce | director | 0 0% | $0 | 0 | 26 | |
| Albers Jeffrey W. | director | 0 0% | $0 | 0 | 7 | |
| Esposito Pamela | director | 0 0% | $0 | 0 | 7 | |
| Ridloff Elena | director | 0 0% | $0 | 0 | 5 | |
| Atlas Venture Fund X, L.P. | 10 percent owner | 828830 1.0076% | $63.75M | 0 | 12 | |
| LAMPERT MARK N | 257754 0.3133% | $19.82M | 4 | 0 | +55.87% | |
| Chiniara Ellen | Chief Legal Officer | 80085 0.0974% | $6.16M | 0 | 3 | |
| Caughey Elaine | Chief Business Officer | 18986 0.0231% | $1.46M | 0 | 1 | |
| Horobin Joanna | director | 0 0% | $0 | 0 | 1 | |
| ATLAS VENTURE ASSOCIATES X, L.P. | 10 percent owner | 0 0% | $0 | 0 | 2 | |
| Chesworth Richard | Chief Scientific Officer | 0 0% | $0 | 0 | 2 |
$159,914,414 | 243 | 18.52% | $8.32B | |
$108,876,545 | 67 | 72.81% | $8.48B | |
$104,428,685 | 44 | 22.55% | $5.69B | |
$477,065,869 | 34 | 82.05% | $6.49B | |
$150,253,463 | 26 | -52.83% | $6.15B | |
$11,859,102 | 17 | 18.62% | $8.52B | |
$103,944,213 | 17 | 5.95% | $6.03B | |
$57,686,748 | 13 | 21.11% | $6.11B | |
Kymera Therapeutics, Inc. (KYMR) | $75,296,863 | 13 | 33.79% | $6.33B |
$9,976,473 | 12 | 29.52% | $5.29B | |
$2,477,801 | 11 | 4.98% | $7.38B | |
$35,908,794 | 10 | 126.31% | $6.81B | |
$20,831,864 | 10 | 69.29% | $5.46B | |
$25,064,843 | 9 | 12.75% | $5.46B | |
$55,713,031 | 8 | -0.36% | $7.59B | |
$2,246,813 | 6 | 70.15% | $6.64B | |
$41,376,000 | 4 | -12.07% | $6.77B | |
$50,990,767 | 2 | 19.79% | $5.26B | |
$7,600,000 | 1 | -4.05% | $5B |
| Increased Positions | 165 | +78.95% | 14M | +17.72% |
| Decreased Positions | 92 | -44.02% | 5M | -6.67% |
| New Positions | 68 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 421,479 | Sold Out |
| Total Postitions | 282 | +34.93% | 90M | +11.05% |
| Baker Bros. Advisors Lp | $483,958.00 | 8.42% | 6.65M | 0 | 0% | 2025-09-30 |
| Avoro Capital Advisors Llc | $462,026.00 | 8.04% | 6.35M | -205,555 | -3.14% | 2025-09-30 |
| Fmr Llc | $427,800.00 | 7.44% | 5.88M | +447,617 | +8.24% | 2025-09-30 |
| Bvf Inc/Il | $400,377.00 | 6.97% | 5.5M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $394,484.00 | 6.86% | 5.42M | -198,126 | -3.52% | 2025-09-30 |
| Wellington Management Group Llp | $378,038.00 | 6.58% | 5.2M | -176,370 | -3.28% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $370,885.00 | 6.45% | 5.1M | -2M | -25.69% | 2025-09-30 |
| Atlas Venture Life Science Advisors, Llc | $356,267.00 | 6.2% | 4.9M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $317,630.00 | 5.53% | 4.37M | +217,188 | +5.24% | 2025-09-30 |
| Siren, L.L.C. | $249,432.00 | 4.34% | 3.43M | 0 | 0% | 2025-09-30 |